60 results on '"Martinez, Felipe"'
Search Results
2. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
3. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial
4. A variable temperature neutron diffraction study of dual ion conducting Sr3V2O8
5. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
6. Gut-liver axis calibrates intestinal stem cell fitness
7. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
8. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
9. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
10. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
11. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
12. The first Miocene fossils from coastal woodlands in the southern East African Rift
13. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER
14. The genetic history of the Southern Andes from present-day Mapuche ancestry
15. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
16. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF
17. The Attitudes of Physicians Toward Guideline Recommendations for the Management of Dyslipidemia in Clinical Practice - The VIPFARMA ISCP Project
18. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER
19. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
20. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
21. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
22. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
23. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
24. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
25. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial
26. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
27. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial
28. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
29. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
30. Rictor/Mammalian Target of Rapamycin Complex 2 Signaling Protects Colonocytes from Apoptosis and Prevents Epithelial Barrier Breakdown
31. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial
32. Incidence and Outcomes of Pneumonia in Patients With Heart Failure
33. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study
34. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
35. Pt(II) and Pd(II) complexes with a thiazoline derivative ligand: Synthesis, structural characterization, antiproliferative activity and evaluation of pro-apoptotic ability in tumor cell lines HT-29 and U-937
36. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
37. Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial
38. An Unusual Presentation: High-Grade Serous Carcinoma of the Fallopian Tube Manifesting With Altered Mental Status Secondary to a Single Brain Metastasis—A Case Report and Review of the Literature
39. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
40. P488: Implementation strategies to improve access to genetic services in a low-resources setting: Experience in Chile’s Valparaíso region
41. A Polypill Strategy to Improve Adherence: Results From the FOCUS Project
42. Chapter 11 - Catalytic synthesis of biosourced polyesters from epoxides and cyclic anhydrides
43. Radiographic manifestations of transfusion-related acute lung injury
44. Predicting the need of tracheostomy amongst patients admitted to an intensive care unit: A multivariate model
45. Absolute eosinophils count as a marker of mortality in patients with severe sepsis and septic shock in an intensive care unit
46. SYMPTOM-PROMPTED, SELF-ADMINISTERED INTRANASAL ETRIPAMIL FOR TERMINATION OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA IN THE RAPID STUDY: RELATIONSHIP AMONG ETRIPAMIL-INDUCED REDUCTION IN TACHYCARDIA RATES, CONVERSION TO SINUS RHYTHM, AND IMPROVEMENT IN PATIENT SYMPTOMS
47. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL
48. THE EFFECT OF DAPAGLIFLOZIN ON DAYS OF FULL HEALTH LOST DUE TO DEATH, HOSPITALIZATION, AND IMPAIRED WELL-BEING IN DAPA-HF
49. MP-453091-1 EFFECT OF ETRIPAMIL NASAL SPRAY ON VENTRICULAR RATE IN PATIENTS EXPERIENCING SYMPTOMATIC ATRIAL FIBRILLATION
50. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.